We are pleased to announce that we will attend BIO-Europe Autumn, a premier event spanning the global life science ecosystem to propel dealmaking and innovation.
Take this opportunity to connect with our delegates and discover how we can help you to structure your drug development process into a series of clear and reachable value inflection points to create an innovative product that brings medical value to patients.
Want to meet at Bio Europe? Contact us to set up a meeting.
In this interview, Joris Pezinni provides an analysis of the current biotech industry, major trends, and the three fundamental functions that executives must address.
Biotech expert Joris Pezzini and Chris Rao, Senior Vice President of Clinical Operations, discuss one of the most crucial aspects of execution: clinical trials.
A biotech company sought support in the design of their Phase II clinical trial to test the safety and efficacy of a novel inhibitor in combination with Pembrolizumab in patients with Head and Neck Squamous Cell Carcinoma.
A US biopharma needed to validate the patient journeys and US reimbursement pathways for their two alpha-emitting radioligand therapies in two solid tumor indications. They also sought to understand the suitable price points for each asset.
A European biotech specializing in the development of radioligand therapies (RLTs) sought to assess the sales potential of its drug candidate, considering the current and future market landscape, especially the positioning of prostate-specific membrane antigen-targeting RLTs.